Furthermore, the aim of this study was not to diagnose previously unrecognized CPS, but to describe the mutational landscape of variants in known CPGs and to identify potential indicators of increased SMN risk in pediatric ALL patients. The gene discussed is CAD; the disease is acute lymphoblastic leukemia.